Avidity Biosciences initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Ananda Ghosh initiated coverage of Avidity Biosciences (RNA) with a Buy rating and $72 price target Three clinical programs establish Avidity’s Antibody Oligonucleotide Conjugate platform for future pipeline diversification, the analyst tells investors in a research note. The firm says the company “finds itself in an enviable position” where it has not only established and de-risked the AOC platform but has executed three clinical programs on difficult to treat rare diseases.